翻訳と辞書 |
Radotinib
Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors, such as patients resistant or intolerant to the drug Imatinib (Gleevec, Glivec). Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea〔http://www.ilyang.co.kr/english/rnd/rnd03.asp〕 and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea.〔http://www.dailypharm.com/Users/News/EnglishNews.html?NewsID=3108&nStart=1023&mode=&searchValue=〕 Radotinib completed a multi-national Phase II clinical trial study in 2012〔http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077080/〕 and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication.〔https://clinicaltrials.gov/ct2/show/NCT01511289?term=radotinib&rank=1〕 Its mechanism of action involves inhibition of the tyrosine kinase Bcr-Abl and of platelet-derived growth factor receptor (PDGFR). ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Radotinib」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|